Neose Technologies
Inc. About
Neose Technologies Neose is a biopharmaceutical company
focused on improving protein therapeutics
using its proprietary technologies. The
Company’s core business is to use its
novel GlycoAdvance™ and GlycoPEGylation™ Technology and Product Candidates Neose’s various technologies evolve from
the same core – the use of enzymes to
complete and modify carbohydrate structures
on glycoproteins. We have developed a
unique expertise and a strong intellectual
property position in this area. The technology
core is broadly applicable and renewable,
providing an opportunity for sustainable
growth as new applications are developed.
Neose is using its GlycoAdvance and GlycoPEGylation
technologies to develop proprietary drug
candidates, as well as to partner with
biotech and pharmaceutical companies.
Our primary focus is developing next generation
therapeutic proteins that are improved
versions of currently marketed proteins
with proven efficacy. GlycoConjugation
is an emerging application of the Company’s
technology. It has the potential to produce
novel therapeutic glycoproteins by conjugating
bioactive or functional compounds to the
glycans on antibodies and other glycoproteins.
technologies to improve proteins for which
there is already a substantial body of
data demonstrating safety and efficacy.
The Company intends to apply its technologies
to products it is developing on its own
and to products it co-develops and co-owns
with others. It also expects to make its
technologies available, through strategic
partnerships, to improve the products
of other parties. Our First Proprietary Candidates We have
targeted improved versions of erythropoietin
(EPO) and granulocyte colony stimulating
factor (G-CSF) as the first two candidates
in our proprietary drug development program
More
on Neose Technologies Inc ntec